Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal ...
ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...
The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...
Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...
At the first sign of a runny nose many people dash out to buy a cold and flu remedy - but soon that might become harder to do ...
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.
The U.S. Food and Drug Administration (FDA) has taken a pivotal step in consumer protection by proposing the removal of oral phenylephrine as an active ingredient in over-the-counter ...
The US Food and Drug Administration (FDA) has proposed an order to ban a popular ingredient in cold and flu medicines as it is seemingly not as effective as other methods. Oral phenylephrine is often ...
Health experts have argued that UK customers are being hoodwinked by the drug firms behind the 'useless' medicines - which include Sudafed, Lemsip and Beechams.
When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.
Sudafed, Mucinex, Benadryl, Advil, Tylenol, Vicks, and Dimetapp. These popular brand names appear on oral decongestants that ...
LTR Pharma and EZZ Life Sciences have been promoted to a flagship global microcaps index, at the expense of Opthea.